🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our manuscript/case report on “Fulminant celiac disease with combination ICI therapy” is now published in Frontiers. We discussed an unusual irAE with severe clinical presentation. Kerry Reynolds @megcamps Florian J. Fintelmann Vikram Deshpande Society for Immunotherapy of Cancer bit.ly/3uNX8fo

🫁 Dr. Meghan Mooradian of MassGeneral News discusses pearls to managing irAEs in patients with metastatic #NSCLC for #ASCODailyNews 💬 fal.cn/3oaE9 #lcsm @megcamps

The diagnosis 🩺 + treatment of lung cancer 🫁 in patients with interstitial lung disease aka 🫁 fibrosis remains a challenge. Download our multidisciplinary take on the current status of potential treatment strategies authors.elsevier.com/a/1fhP87iQyxEe…

If you are Society for Immunotherapy of Cancer #SITC2022 Come by our poster #1253 where we present a descriptive analysis of lung cancer patients that were admitted for confirmed immunotherapy toxicities. #irAEs @megcamps Kerry Reynolds Hem-Onc Fellows Network

World-renowned experts speak at the West Cancer Center & Research Institute's Conference on Feb. 4-5, 2023.​ Join the program in-person at the Guest House at Graceland + earn 8 CME credits. Learn more: bit.ly/3ESfr5N Brad Somer @wadavidal Axel Grothey​ Heather McArthur, MD, MPH, FASCO Edith Mitchell, M.D. @megcamps Brian Van Tine

📣Virtual Tumor Board on Tuesday, May 30. Register to join us for an in-depth discussion on #AcralMelanoma. ow.ly/hEwt50OxAWE. Genevieve Boland, MD, PhD @JHuiMD @megcamps

Over 800 police officers were at the parade today and over a million civilians who were allowed to be armed. Yet they couldn't stop a dozen people from being shot. More guns makes us less safe. #ChiefsParade kmbc.com/article/shooti…

So proud of this joint effort! Over 30 experts came together to create a Delphi consensus guideline for the diagnoses of cutaneous irAE from checkpoint inhibitors!!! Thanks to all our wonderful collaborators, including the team at Project Datasphere! #onctwitter #dermtwitter

⁦Nature Communications⁩ ⁦Florian J. Fintelmann⁩ Amazing collaborative effort! merging immunotherapy and intratumoral cryoablation to overcome ICI resistance in melanoma. nature.com/articles/s4146…

Very proud of amazing Ginny Sun, MD from MGH IM Residents. Co-led with Kerry Reynolds from Mass General Cancer Center. Large language models with an excellent sensitivity and specificity for several key ICI associated adverse events and in 9 secs. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

SITC’s new Melanoma CPG Addendum addresses the changing treatment landscape driven by the first approved solid tumor cell therapy, lifileucel, and practice-changing guidance from the NADINA trial. Learn more here: ow.ly/5G0w50VlqHK #SITCGuidelines #Melanoma #Immunotherapy

Excellent presentation by Meghan Mooradian from ADuong presenting UPMC Hillman Cancer Center led Neo-Mel-T trial evaluating neoadjuvant anti-TIM-3+anti-PD-1 vs. neoadjuvant anti-PD-1 in high-risk resectable #melanoma. MPR 56%, 1-year RFS 87% with no surgical delays, 15%TRAE with dostar/cobo

Neoadjuvant cobolimab & dostarlimab followed by surgery & adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in high-risk, resectable melanoma. Research presented at #ASCO25 by Meghan Mooradian of MassGeneral News. #skcsm #melsm shorturl.at/QpS8W